Clinical trials update from the Heart Failure Society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF
Clinical trials update from the Heart Failure Society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF
复制标题
DOI：
10.1016/j.ejheart.2006.10.001
复制
发表时间：
2006-11-01
影响因子：
18.2
通讯作者：
Clark, Andrew L.
中科院分区：
文献类型：
--
作者：
Cleland, John G. F.;Coletta, Alison P.;Clark, Andrew L.
本文提供了与心力衰竭的病理生理学、预防和治疗相关的试验的信息和评论，这些试验在 2006 年 9 月在西雅图举行的美国心力衰竭协会会议上提出。所有报告均应被视为初步数据，因为最终出版物中的分析可能会发生变化。在 FIX-CHF-4 研究中，旨在改善心脏收缩力的设备可能会改善运动耐量和生活质量；然而，审判解释存在不确定性。一项报告首次向人类志愿者施用选择性肌球蛋白激活剂 CK-1827452 的研究结果支持在心力衰竭患者中启动临床试验。在 OPT-CHF 中，与安慰剂相比，奥嘌呤醇未能显示出治疗心力衰竭的益处，尽管回顾性亚组分析表明它可能对血清尿酸水平升高的患者有益。 (c) 2006 年欧洲心脏病学会。由 Elsevier B.V 出版，保留所有权利。
This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure, presented at the Heart Failure Society of America meeting held in Seattle in September 2006. All reports should be considered as preliminary data, as analyses may change in the final publication.Devices designed to improve cardiac contractility may have improved exercise tolerance, and quality of life in the FIX-CHF-4 study; however, uncertainties in trial interpretation exist. The results of a study reporting the first administration of the selective myosin activator CK-1827452 to human volunteers, support the initiation of clinical trials in heart failure patients. In OPT-CHF, oxypurinol failed to show benefit compared to placebo for the treatment of heart failure, although a retrospective subgroup analysis suggests that it may be beneficial in patients with elevated serum uric acid levels. (c) 2006 European Society of Cardiology. Published by Elsevier B.V All rights reserved.